196 related articles for article (PubMed ID: 32554315)
21. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
Sato S; Kunisaki C; Tanaka Y; Sato K; Miyamoto H; Yukawa N; Fujii Y; Kimura J; Takagawa R; Takahashi M; Kosaka T; Akiyama H; Saigusa Y; Taguri M; Yamanaka T; Endo I
Anticancer Res; 2018 Dec; 38(12):6911-6917. PubMed ID: 30504409
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Sasaki Y; Nishina T; Yasui H; Goto M; Muro K; Tsuji A; Koizumi W; Toh Y; Hara T; Miyata Y
Cancer Sci; 2014 Jul; 105(7):812-7. PubMed ID: 24716542
[TBL] [Abstract][Full Text] [Related]
25. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).
Minard-Colin V; Ichante JL; Nguyen L; Paci A; Orbach D; Bergeron C; Defachelles AS; André N; Corradini N; Schmitt C; Tabone MD; Blouin P; Sirvent N; Goma G; Geoerger B; Oberlin O
Eur J Cancer; 2012 Oct; 48(15):2409-16. PubMed ID: 22633624
[TBL] [Abstract][Full Text] [Related]
27. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
[TBL] [Abstract][Full Text] [Related]
28. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
29. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Metts JL; Alazraki AL; Clark D; Amankwah EK; Wasilewski-Masker KJ; George BA; Olson TA; Cash T
Pediatr Blood Cancer; 2018 Sep; 65(9):e27246. PubMed ID: 29770997
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
32. Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.
Bochennek K; Dantonello T; Koscielniak E; Claviez A; Dirksen U; Sauerbrey A; Beilken A; Klingebiel T
Klin Padiatr; 2013 Nov; 225(6):309-14. PubMed ID: 23946091
[TBL] [Abstract][Full Text] [Related]
33. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Biganzoli L; Cinieri S; Berardi R; Pedersini R; McCartney A; Minisini AM; Caremoli ER; Spazzapan S; Magnolfi E; Brunello A; Risi E; Palumbo R; Leo S; Colleoni M; Donati S; De Placido S; Orlando L; Pistelli M; Parolin V; Mislang A; Becheri D; Puglisi F; Sanna G; Zafarana E; Boni L; Mottino G
Breast Cancer Res; 2020 Aug; 22(1):83. PubMed ID: 32758299
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
[TBL] [Abstract][Full Text] [Related]
35. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
36. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
[TBL] [Abstract][Full Text] [Related]
37. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
38. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S
BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236
[TBL] [Abstract][Full Text] [Related]
39. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
40. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
